ARTICLE | Clinical News
InflaRx stumbles after C5a mAb fails in inflammatory skin disease study
June 5, 2019 7:44 PM UTC
After reporting a high clinical response rate in a Phase IIa study, InflaRx lost $34.28 (92%) to $3.01 in afternoon trading Wednesday after all doses of IFX-1 failed to meet the primary endpoint in the Phase IIb SHINE trial to treat moderate to severe hidradenitis suppurativa.
In the 179-patient study, four different doses of the mAb against C5a failed to improve Hidradenitis Suppurativa Clinical Response (HiSCR) rates at week 16 vs. placebo. According to InflaRx N.V. (NASDAQ:IFRX), placebo led to an unusually high HiSCR rate of 47.1% compared with 38.7-51.5% for the various doses of IFX-1...
BCIQ Company Profiles
BCIQ Target Profiles